Precipio (PRPO) Expected to Post Earnings on Wednesday

Precipio (NASDAQ:PRPO) is anticipated to release its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect Precipio to post earnings of ($2.00) per share and revenue of $1.6750 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.

Precipio (NASDAQ:PRPO) last announced its earnings results on Thursday, May 14th. The biotechnology company reported ($0.81) earnings per share (EPS) for the quarter. Precipio had a negative return on equity of 6.73% and a negative net margin of 3.57%.The business had revenue of $6.71 million for the quarter.

Precipio Stock Up 1.3%

PRPO stock opened at $23.70 on Wednesday. The company has a market cap of $42.42 million, a price-to-earnings ratio of -50.43 and a beta of 1.27. The company has a fifty day moving average price of $23.99 and a 200 day moving average price of $25.19. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.56 and a quick ratio of 1.33. Precipio has a 12 month low of $13.02 and a 12 month high of $33.63.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in PRPO. Geode Capital Management LLC lifted its position in shares of Precipio by 5.1% during the 4th quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock valued at $377,000 after acquiring an additional 789 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Precipio by 10.7% during the 4th quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock worth $333,000 after acquiring an additional 1,400 shares in the last quarter. Finally, Susquehanna International Group LLP acquired a new stake in shares of Precipio in the 3rd quarter worth approximately $194,000. 10.45% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently commented on PRPO shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precipio in a report on Friday. Wall Street Zen lowered Precipio from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

About Precipio

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.